Expanding the use of hepatitis C–viremic kidney donors

Academic Article

Abstract

  • © 2017 International Society of Nephrology Direct-acting antivirals have revolutionized the treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease, with implications for the timing of antiviral treatment among kidney transplant candidates and for the use of HCV viremic donors. A recent consensus conference reviewed the available data on the safety and cost-effectiveness of expanding access to HCV-positive organs to HCV-negative recipients. Early trials are promising, but larger trials and a plan for obtaining HCV therapy in the posttransplantation period are needed. Implications for the larger transplant community also need to be considered.
  • Authors

    Digital Object Identifier (doi)

    Author List

  • Sawinski D; Wyatt CM; Locke JE
  • Start Page

  • 1031
  • End Page

  • 1033
  • Volume

  • 92
  • Issue

  • 5